Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab

Arcus Biosciences (RCUS) Misses Q3 EPS by 5c

November 8, 2021 4:28 PM EST

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.11), $0.05 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $9.46 million versus the consensus estimate of $9.47 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

... More